Elevation Oncology, Inc. (ELEV)
| Market Cap | 213.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 1.05M |
| EPS (ttm) | -25.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 976 |
| Open | - |
| Previous Close | 9.21 |
| Day's Range | 9.34 - 9.34 |
| 52-Week Range | 7.71 - 16.22 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 23.67 (+153.4%) |
| Est. Earnings Date | Nov 11, 2021 |
About ELEV
Elevation Oncology is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. We utilize our deep expertise in developing drugs for rare, genomically-defined patient populations and strategic collaborations with our diagnostic collaborators to work towards a future where each tumor’s unique genomic test result can be matched with a purpose-built precision medicine. Our lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genom...
Financial Performance
Financial StatementsNews
Elevation Oncology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 7, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology Reports Second Quarter 2021 Financial Results
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology to Present at the 12th Annual Wedbush PacGrow Healthcare Conference
NEW YORK, Aug. 4, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically...
Elevation Oncology Announces Pricing of Initial Public Offering
NEW YORK, June 24, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomicall...
Elevation Oncology IPO Registration Document (S-1)
Elevation Oncology, Inc. has filed to go public with an IPO on the NASDAQ.